Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and “New Old Friends”

Thomas-Oliver Kleen1*, Alicia A. Galdon2, Andrew S. MacDonald2 and Angus G. Dalgleish3*

1 Immodulon Therapeutics Limited, Uxbridge, United Kingdom, 2 Lydia Becker Institute of Immunology and Inflammation, Manchester Collaborative Centre for Inflammation Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 3 Institute for Infection and Immunity, St George’s, University of London, London, United Kingdom

The novel, highly contagious coronavirus SARS-CoV-2 spreads rapidly throughout the world, leading to a deadly pandemic of a predominantly respiratory illness called COVID-19. Safe and effective anti-SARS-CoV-2 vaccines are urgently needed. However, emerging immunological observations show hallmarks of significant immunopathological characteristics and dysfunctional immune responses in patients with COVID-19. Combined with existing knowledge about immune responses to other closely related and highly pathogenic coronaviruses, this could forebode significant challenges for vaccine development, including the risk of vaccine failure. Animal data from earlier coronavirus vaccine efforts indicate that elderly people, most at risk from severe COVID-19 disease, could be especially at risk from immunopathologic responses to novel coronavirus vaccines. Bacterial “new old friends” such as Bacille Calmette-Guérin (BCG) or Mycobacterium obuense have the ability to elevate basal systemic levels of type 1 cytokines and immune cells, correlating with increased protection against diverse and unrelated infectious agents, called “trained immunity.” Here we describe dysfunctional immune responses induced by coronaviruses, representing potentially difficult to overcome obstacles to safe, effective vaccine development for COVID-19, and outline how trained immunity could help protect high risk populations through immunomodulation with BCG and other “new old friends.”

Keywords: COVID-19, SARS, dysfunctional immune response, vaccine, trained immunity, BCG, IMM-101, Mycobacterium obuense

INTRODUCTION

In recent months, a novel severe acute respiratory syndrome (SARS) coronavirus (CoV), SARS-CoV-2, which causes COVID-19, has spread rapidly throughout the world (1). As of July 15, 2020, more than 13 million infections and over 575,000 COVID-19 related deaths have been confirmed worldwide. Based on a chronic lack of adequate testing capabilities in many countries worldwide,
including large industrialized nations like the United States, a large amount of undiagnosed infection and mortality from COVID-19 must be assumed. The unprecedented pandemic seriously challenges the world’s health care systems and available hospital capacities to treat seriously ill patients. These challenges are amplified by frequent SARS-CoV-2 infection of healthcare workers (HCW), leading to hospital-acquired infection of HCW and patients, and significant mortality within that group (2). Other high-risk groups of infection include the elderly, with age-related immunosenescence and “inflammaging” having been suggested as a mechanism responsible for lowered immunological competence and the high mortality of the elderly in the current COVID-19 pandemic (3). Age-related risks are a particular issue in assisted care facilities and individuals with serious, non-COVID underlying health conditions like cardiovascular disease, chronic kidney disease, diabetes, chronic respiratory disease, immunosuppression, and cancer (4, 5). In the case of cancer, many malignancies require active treatment, making isolation – even social distancing – impossible, based on the need to commute to the hospital regularly to receive treatments. Therefore, there is an urgent need to protect individuals aged 55 years and older with co-morbidities. Throughout the public discourse, there has been little attention given to the observations that these populations are historically the same populations that are most unlikely to develop efficient and protective immune responses to standard respiratory viruses. Consequently, this is likely to be the same case for SARS-CoV-2. Indeed, for these populations, other more potent vaccines, compared to the general population, are required, e.g., “high dose” Influenza shots for the elderly. Nevertheless, those more potent vaccines often still result in less than ideal outcomes in these vulnerable populations (6). In order to avoid the need for achieving herd immunity by infection or mass vaccinations before safely reopening societies and economies, a priority would be immunizing the most at-risk populations first. There is a justified concern that suboptimal vaccine efficacy for at-risk populations and the elderly could place the goal of not having to achieve herd immunity first in jeopardy. At the same time, a non-efﬁcacious vaccine for at-risk populations could increase the probability of second and subsequent waves of infection in these populations (7).

Worldwide availability of safe, effective, prophylactic vaccines is likely the only approach that will ultimately control this deadly pandemic. However, such vaccines may not be available until early next year, even in the most optimistic scenarios (8). Despite numerous efforts, no vaccine, proven safe and effective in humans, has ever been developed against any coronavirus (9, 10). Questions about the potential lack of sufﬁcient vaccine efﬁcacy in elderly populations have not yet been widely discussed. Therefore, strategies to prevent COVID-19 morbidity and mortality in high risk groups are desperately needed in order to safeguard the most vulnerable individuals, as well as maintaining continuous patient care and functioning hospital systems.

Both humans and animals are susceptible to disease caused by CoVs. Three highly pathogenic CoVs are known, SARS-CoV, Middle East respiratory syndrome (MERS)-CoV and SARS-CoV-2. All three are now known to efficiently infect and replicate in the lower respiratory tract, frequently causing substantial immunopathology, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and fatal pneumonia, resulting in high morbidity and mortality (11). SARS-CoV and SARS-CoV-2 are both members of the betacoronavirus genus and share more than 70% of their genetic code (12). However, it is noteworthy that SARS-CoV-2 is closest related to the bat coronavirus RaTG13, with 98% genetic similarity compared to all known genetic coronavirus sequences (13). Four additional, circulating but low pathogenic human coronaviruses (HCoV) are known and will not be reviewed here, but preexposure to them could impact the immune response to SARS-CoV-2 in patients (14).

All four, HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, display a winter seasonality, causing comparatively mild bronchiolitis and pneumonia symptoms (15, 16). All HCoVs share a minimum of four, genome encoded, major structural proteins: the spike (S) glycoprotein, nucleocapsid (N) protein, membrane protein (M), and the envelope protein (E), all of which are required to produce a structurally complete viral particle (17).

**IMMUNE RESPONSES TO CORONAVIRUSES**

The pandemic, which originally emerged from Wuhan, China, has been characterized by a rapidly increasing morbidity and mortality rate associated with older age, beginning around age 50 years (18). Multiple aspects of immunity can be influenced by ageing, prompting scrutiny of which components of the immune response might be responsible for higher mortality in older people (19). In general, an early and robust innate immune response to viral infections permits more rapid and effective viral clearance and may even prevent symptomatic infection or diminish the severity of the infection (20). No correlates of protection have yet been formally established for the recently emerged SARS-CoV-2. However, mouse model data from studies with the first SARS-CoV that emerged in 2002, suggested a delayed innate immune response during infection is linked to a more severe course, with immunopathology in the lungs and high mortality (21). Initial observational studies suggest that a failure of antiviral immunity, including depleted natural killer (NK) cells, at an early stage in COVID-19, may lead to severe clinical course and an inability to recover from infection (22). In addition, it has previously been shown that the SARS-CoV macrodomain suppresses the innate immune response during infection, whereas an early strong innate immune response can protect mice from lethal disease and prevent detrimental downstream effects on the immune system (23). On the other hand, in later stages of infection, it appears that a dysregulated immune system, including excessive inflammatory responses by innate cells in the lungs, and selective immunosuppression of the adaptive immune system, can be detrimental for the host (24, 25). Acute lung injury caused by viruses like respiratory syncytial virus, influenza A virus and SARS-CoV have been described previously (11, 26, 27). Aberrant expression of the antiviral cytokine type I interferon (IFN), interferon stimulated...
genes, and other inflammatory cytokines, were observed in patients with severe SARS-CoV disease compared to healthy individuals, providing evidence that SARS-CoV is partly an innate dysregulated immune disease (28, 29).

The innate immune system recognizes pathogen-associated molecular patterns (PAMPs) of viral or bacterial intruders via pattern recognition receptors (PRRs). Toll-like receptors (TLRs), a family of type I transmembrane PRRs that consists of related, transmembrane proteins, play a central role in the initiation of inflammatory responses against pathogens, including the secretion of cytokines and chemokines. TLR4 is known to sense lipopolysaccharide (LPS) from gram-negative bacteria, but, based on its additional function as sensor for damage-associated molecular patterns (DAMPs), TLR4 has been suggested to play a central role in the induction of damaging inflammatory responses during several acute viral infections (30). In addition, oxidized phospholipids (OxPLs), DAMPs which lead to ALI in patients infected with SARS-CoV-2, also accumulate in lungs of patients infected with SARS-CoV-2 and activate monocyte-derived macrophages through TLR4 (31, 32). Interfering with innate cell activation by TLR4 in response to ligands such as OxPLs may therefore help prevent thrombotic complications, recently identified as a major factor in mortality of COVID-19 patients (33–35). Endothelial cell activation, infection and dysfunction has been implicated in severe COVID-19 by altering vessel barrier integrity, promoting a pro-coagulative state, inducing vascular inflammation, endotheliitis, and mediating inflammatory cell infiltration. The proposed mechanism is disruption of vascular integrity and endothelial cell death, which leads to exposure of the thrombogenic basement membrane and results in the activation of the clotting cascade (36). Altered platelet gene expression and functional responses in patients infected with SARS-CoV-2 may additionally contribute to observed hemostatic abnormalities like disseminated intravascular coagulopathy (37).

**Neutrophils**

Neutrophils are an important component of the general response to infection in the respiratory system and capable of recognizing viruses via viral PAMPs (38). In the context of potentially excessive neutrophil activation in late stage COVID-19 disease, neutrophil extracellular traps (NETs) in the lungs can drive severe pathologies by accumulation of mucus in the airways of patients, contributing to ARDS (39). More importantly, NETs have been proposed to contribute to organ damage and mortality, since excess NET formation can trigger a cascade of inflammatory reactions that destroys surrounding tissues and facilitates atherosclerosis, aortic aneurysms, as well as thrombosis, including microthrombosis, in the vascular system, with devastating effects on organ function (39).

**Macrophages**

Macrophages are key innate immune cells in any infection setting (40, 41). They are highly flexible innate cells that can, simplistically, be functionally and phenotypically divided into pro-inflammatory “M1” macrophages (capable producers of inflammatory cytokines and mediators, that kill infectious organisms, virus-infected cells, or tumor cells) and more regulatory “M2” macrophages (that are important for wound healing and parasite infections) (42, 43). Both activation states are needed for a “balanced” immune response, although the M1/M2 paradigm of macrophage activation is an over-simplistic definition of these complex and diverse innate cells (44, 45). During ageing and chronic inflammatory diseases, macrophages may switch to a more M2-like phenotype (46, 47). Importantly, nearly all identified high-risk factors for severe COVID-19 disease, like cardiovascular disease, diabetes, age, chronic obstructive pulmonary disease, and smoking, generally share a shift from more M1 to more M2 phenotype and function (48). Classical activation of M1 macrophages is induced by LPS/IFN-γ exposure, while alternatively activated M2 macrophages are stimulated by IL-4, IL-10, IL-13 and glucocorticoids (49). The activation of innate immune cells such as macrophages can be heavily influenced by the character of the T cell response and, in particular, the cytokines produced by T cells during infection (50). SARS-CoV replication has previously been shown in human peripheral monocytes and macrophages, with varying efficacy. Importantly, the infection efficiency was shown to be donor dependent, with 100% infection in some and less than 5% in others (51).

**γδ-T Cells**

In adults, Vγ9Vδ2 cells are the dominant γδ T cell population, however, in elderly individuals the variability increases (52, 53). An analysis of T cell repertoires in HCW who survived SARS-CoV infection during the 2003 outbreak revealed that an innate-like subpopulation of effector memory T cells, γδ-T cells, specifically Vγ9Vδ2 T cells, were selectively expanded approximately 3 months after the onset of disease (54). Importantly, no such expansion of non-innate αβ T cells was detected at the same time point. Furthermore, expansion of the Vγ9Vδ2 T cell population was associated with higher anti-CoV IgG titers, and *in vitro* experiments demonstrated that Vγ9Vδ2 T cells display an IFN-γ-dependent ability to directly kill CoV infected target cells. Therefore, innate-like Vγ9Vδ2 T cells may play a protective role during SARS-CoV and other CoV infections. A recent study analyzed the number and activation status of Vγ9Vδ2 T cells in hospitalized patients with COVID-19. They found significantly lower levels of Vγ9Vδ2 T cells than that of matched healthy control and concluded that this could indicate that elderly with lower frequencies of Vγ9Vδ2 T cells constitute a SARS-CoV-2 vulnerable population or that the Vγ9Vδ2 T cells in these patients have migrated to the lungs to kill SARS-CoV-2 infected cells (55).

**T Cells and NK Cells**

SARS-CoV infection leads to lymphopenia and strongly reduced peripheral T cell levels, with low CD4+ and CD8+ T cell counts associated with adverse outcome, and a rapid and dramatic restoration of peripheral T cell subsets in the periphery of recovering patients (56–58). In addition, SARS-CoV can infect and replicate within PBMCs of SARS-CoV patients, with viral replication appearing to be self-limiting but leading to leukopenia or lymphopenia (59–61). Patients with clinical symptoms of severe COVID-19 also commonly present with lymphopenia,
SARS-CoV elicited recall CD8+ T cell secretion of IFN-γ 2 years after infection (72–74). S protein-derived epitopes of specific memory CD4+ and CD8+ T cells persisted for up to Multiple other independent studies established that SARS-CoV-recovered individuals, where CD8+ T cell responses targeting the SARS-CoV membrane and nucleocapsid proteins were found to persist up to 11 years post-infection (70). Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection indicated that the majority of memory CD8+ T cells produced IFN-γ, whereas memory CD4+ T cells produced IFN-γ, IL-2, or TNF-α (71). Multiple other independent studies established that SARS-CoV specific memory CD4+ and CD8+ T cells persisted for up to 2 years after infection (72–74). S protein-derived epitopes of SARS-CoV elicited recall CD8+ T cell secession of IFN-γ as well as intracellular production of IFN-γ, TNF-α, perforin, and granzyme A from recovered patients over 1 year post infection, indicating that SARS-CoV infection can induce strong and long-lasting cytotoxic T lymphocyte (CTL)-mediated immunity in patients (75, 76). High frequencies of CD8+ Tc1-type T cells, reactive against MERS-CoV, were observed in a large proportion of patients with severe and moderate MERS at acute stage before detection of humoral and CD4+ T cell responses. Another report emphasizing the importance of T cells demonstrated that 17 years after the 2003 SARS outbreak, SARS-CoV-recovered patients still maintained long-lasting memory T cells reactive to the N protein of SARS-CoV, which notably exhibited robust cross-reactivity to the N protein of SARS-CoV-2 (77). A recent study showed predominant Th1 responses in convalescing COVID-19 cases, with little to no Th2 responses. It demonstrated SARS-CoV-2 specific CD4+ T cells in 100% of COVID-19 convalescent patients, with the majority of responses against S protein, correlating with the magnitude of anti-SARS-CoV-2 IgG and IgA titers, but as well responses against M and N proteins in all patients, accounting for 11–27% of the total CD4 + responses. The same study found SARS-CoV-2 specific CD8+ cells against S and M proteins in about 70% of patients, and interestingly, T cell reactivity to SARS-CoV-2 epitopes was also detected in non-exposed individuals, likely cross-reactive from previous, seasonal HCoV infections (78). However, at the convalescent phase, the magnitude of the CD8+ T cell response was not increased further. Although it seems clear that robust inflammatory and CTL responses are required to clear the invading virus, when excessive, they can also lead to lung tissue destruction and pneumonia (79). Early pathological findings of COVID-19 patients with ARDS, showed not only reduced counts of peripheral CD4+ and CD8+ T cells, but that remaining T cells were found in a hyperactivated state, with high proportions of HLA-DR and CD38 double-positive fractions (80). It is noteworthy here that, in patients hospitalized with avian H7N9, survival reflected an early, but transient, prevalence of highly activated CD8+CD38+HLA-DR+PD-1+ T cells, but prolonged CD38+HLA-DR+PD1+ co-expression predicted fatal outcomes (81). CD8+ T cells in patients that died of H7N9 were non-functional, as reflected by a lack of IFNγ production, but displayed high and continued expression of the CD38+HLA-DR+ activation markers, together with the inhibitory PD-1 immune checkpoint receptor. Similar studies in Ebola, Dengue, and pandemic H1N1 have also mentioned the presence of these “non-survival” peripheral lymphocyte populations, with high and prolonged frequency of activated CD8+CD38+HLA-DR+ cells (82–84). We hypothesize that, as suggested for H7N9 disease (81), in COVID-19 patients this could also be associated with defective T cell activation and a lack of relevant T cell receptor (TCR) specificities. It is known that infection with human immunodeficiency virus (HIV) induces broad lymphocyte activation, with an increase in T cell activation markers such as CD38 (85). Several studies have shown that such increased CD38+ expression on CD8+ T cells is a strong predictive marker for disease progression in HIV-1 infection (86). Not only does the CD8+CD38+ T cell count predict progression of HIV disease to AIDS and death, but it is also independently predictive for evaluation of high plasma virus load and low CD4+ T cell counts (87). In early HIV infection, during onset of viremia, CD8+CD38+HLA-DR+ T cells correlate inversely with viral set point. However, hyperacute HIV infection leads these cells to be short-lived effector cells that do not persist, characterized by marked apoptosis, upregulation of CD95 and failure to upregulate the IL-7 receptor CD127 (88). Strikingly, in a recent study in COVID-19 patients, considerable proportions of peripheral CD4+ and CD8+ T cells co-expressed CD38 and HLA-DR, but those cells could not be re-activated with peptide pools of the S protein in vitro, supporting the notion of SARS-CoV-2 specific refractory T cells and/or different specificities (14). No data about the PD-1 status of T cells was provided. The same remarkable study showed that, while the majority of S-reactive CD4+ T cells from COVID-19 patients co-expressed CD38 and HLA-DR, S-reactive CD4+ T cells from healthy donors, proposed to be cross reactive to other HCoVs, only expressed CD38 and HLA-DR at very low frequencies and co-expression was not observed. In cancer therapy models, depleting “dysfunctional” CD8+CD38hiPD-1+ cells enhanced therapeutic outcomes, and patients who did not respond to immunotherapy showed more CD8+CD38hiPD-1+ in tumor and blood compared to responders (89). The potential significance of levels and
B Cells and Antibodies
Antibody responses elicited by coronaviruses, including SARS, have been described as comparatively short lived and inconsistent (91, 92). Studies with human volunteers that were infected with a seasonal coronavirus HCoV-229E showed that individuals could get infected and display symptoms, including lymphocytopenia, regardless of preexisting antibodies (91). One study showed that six years post infection, SARS-CoV specific IgG was undetectable in 21 of 23 former patients, and no SARS-CoV specific memory B cell responses could be detected in any of the 23 patients (93). Another study revealed that SARS-CoV antibodies could be seen up to 24 months after infection (93). Interestingly, longevity of MERS-CoV antibody response correlated with disease severity. In one study, patients with severe MERS-associated pneumonia had a persistent antibody response detected for about 18 months after infection, while patients with infection limited to the upper respiratory tract or who had no clinical signs had no detectable MERS-CoV antibody response (94). In another report, the more severe the illness, the greater the antibody response, including IgM, IgG, and neutralizing Ab (NAbs). Patients in the convalescent phase, with mild or asymptomatic disease, rarely developed antibody responses (79). A strong antibody response developed in most MERS patients only after 2–3 weeks of illness, but the antibody responses were not correlated with the elimination of the virus from the body (95, 96). This was confirmed in two more studies that showed MERS infections are frequently characterized by low NAbs, despite patient recovery (93, 97–99). It is noteworthy that this was also recently shown for COVID-19 patients, where seroconversion has been observed in 9 mild to moderate cases after 6–12 days, but, despite COVID-19 antibodies arising at that time, no rapid decline of viral load was observed, as would be expected with highly effective and neutralizing antibodies (100). Since anti-SARS-CoV antibody responses are short-lived in patients who have recovered from SARS, there are early indications that antibodies, and especially NAbs, may not be the predominant mechanism necessary for effective viral clearance and for infected individuals to overcome a COVID-19 infection (10, 101–103). This was further reinforced by the first longitudinal study in COVID-19 patients, which showed that some individuals who have recovered and displayed a strong NAb response shortly after infection, had titers fall as much as 23-fold, and in some cases back to baseline within 3 months (104). The authors speculated that the observed transient NAb response could be a feature shared by both a SARS-CoV-2 infection that causes low disease severity, and the circulating seasonal coronaviruses. Other recent data supports the notion of an unclear role of Abs, by reporting short duration of Ab and NAb titers after SARS-CoV-2 infection. Compared with responses of patients with symptoms, asymptomatic individuals (arguably with the more effective immune response), had weaker Ab responses to infection, with a reduction of IgG levels already occurring in the early convalescent phase (105); viral load and duration of infection are likely to be factors. Remarkably, in this study, 40% of asymptomatic patients had undetectable levels of protective antibodies two to three months after infection, compared to 13% of the symptomatic patients with COVID-19. An even more notable finding, further indicating a limited role for Abs in overcoming SARS-CoV-2 infection, is that intrafamilial exposure to SARS-CoV-2 induces a cellular immune response without seroconversion (106).

SARS Vaccine Challenges
Of the different proteins that characterize coronaviruses, the S protein is an important determinant of virulence, tissue tropism and host range (107). Trimmers of S form the characteristic large spikes on the coronavirus envelope and both SARS-CoV and SARS-CoV-2 use the protein angiotensin converting enzyme 2 (ACE-2) as primary receptor for docking and infecting human host cells. Priming of the virus S protein by host cell proteases is essential for entry. When SARS-CoV-2 docks to the cell via the ACE-2 receptor, the host transmembrane serine protease 2 (TMPRSS2) is responsible for cell entry (108–110). TMPRSS2 also aids the MERS-CoV to penetrate the cell (111), but its primary receptor for entry is dipeptidyl peptidase 4 (DPP4) (112). Virus S glycoproteins are postulated to elicit an immune response in humans that could protect against future infection (108, 113). Many vaccine approaches against COVID-19 that are currently in development are focusing primarily on the generation of antibody responses against the SARS-CoV-2 S protein (8). However, despite the great urgency for making an effective vaccine against COVID-19 available, this approach must be undertaken with great caution. Several SARS-CoV vaccines that initially induced antibodies and short-term protection in mouse models of SARS-CoV led to dysfunctional or type 2 enhanced immunopathology on challenge, with prominent eosinophil infiltration in the lungs, suggesting hypersensitivity to SARS-CoV components was induced (10). Several other independent studies with animal models used to develop vaccine candidates against SARS-CoV exposed signs of lethal vaccine failure based on induction of cell-mediated type 2 enhanced immunopathology, with associated eosinophilic infiltrates causing severe pneumonia, especially in aged mice. A vaccine based on SARS-CoV S protein protected against viral challenge when young mice were vaccinated, but it failed to efficiently protect older mice (114). Another study indicated poor vaccine performance as well as Th2-based eosinophilic immune pathology in the lungs that was shown to be caused by alum adjuvanted and unadjuvanted SARS-CoV vaccines in aged animals (115). All this requires that particular attention be
given to the strongly increased mortality rate already evident in older SARS-CoV-2 patients and patients with comorbidities. SARS-CoV has been shown to dysregulate the immune response in SARS patients by biased activation of a Th2 response, which can counter-regulate the type 1 response that normally attacks bacteria and viruses (97). There was a significant increase in Th2 cytokines IL-4, IL-5 and IL-10 during acute infection in fatal SARS cases, once again indicating that the character of cellular immune response induced by any COVID-19 vaccine will be critical in determining whether it will succeed (101, 116). Four earlier vaccines against MERS-CoV-2 have been tested in rhesus macaques (RM), but no reports of efficacy of a single-dose MERS-CoV vaccine in non-human primates (NHPs) had been made until a recent study reported that RM seroconverted after a single intramuscular vaccination with the experimental ChAdOx1 MERS vaccine (117). The study showed that vaccinated animals developed a neutralizing antibody response, were protected against respiratory injury and pneumonia, and showed reduced viral load in lung tissue and reduced disease severity. In addition, a Phase 1 trial in healthy individuals aged 18–50 years has been conducted, with no adverse safety signal reported (118). Neither study has provided data in either aged animals or elderly humans. Most relevant in this context are early SARS-CoV-2 vaccine trial data. A Phase 1/2 study in adults aged 18 to 55 years of a COVID-19 RNA vaccine candidate (BNT162b1), utilizing mRNA that encodes trimerezed SARS-CoV-2 spike glycoprotein, showed the generation of NAb titers 28 days after the first injection and one week after the second dose (119). It is not yet known what kind of immune response the vaccine will elicit in older people or long-term. An additional mRNA nano-particle based vaccine candidate (mRNA-1273) has been reported to induce both potent Nabs and CD8+ T cell responses and to protect against SARS-CoV-2 infection in the lungs and noses of a mouse model, without evidence of immunopathology (120). Importantly, it showed spike peptide-reactive CD4+ and CD8+ T cells producing IFN-γ, IL-2, and TNF, which would be encouraging if corroborated in ongoing Phase 2 clinical trials and Phase 3 efficacy evaluation of the same vaccine candidate. Another advanced SARS-CoV-2 vaccine candidate in Phase 1 clinical studies is adenovirus-vectorized vaccine ChAdOx1 nCoV-19, which has been reported to prevent SARS-CoV-2 pneumonia in RM and not to be Th2 dominated, determined by IgG subclass and cytokine expression profiling (121). Notably, no evidence of immune-enhanced disease following viral challenge twenty-eight days after vaccination was observed in the respective animals. The levels of Abs produced by the vaccine in these RM were lower than many Ab responses in humans infected with SARS-CoV-2. While the vaccine protected RM from severe infection, they became infected with evident active virus replication, which does not rule out the potential of maintained ability to transmit virus.

Despite the inherent challenges of adopting new routes of routine vaccine administration during an ongoing pandemic, recent evidence would encourage consideration of intranasal administration, inhalation or other vaccine strategies that directly target the mucosal surfaces of the airways, because of distinct functional responses by respective tissue-resident memory T cells (122). It was shown, for example, in a mouse model, that conserved epitopes shared by SARS-CoV and MERS-CoV could induce airway memory CD4+ T cells producing IFN-γ which were phenotypically and functionally different from lung-derived cells and crucial for protection against both CoVs. It is particularly noteworthy in this study that intranasal (but not subcutaneous) vaccination protected mice from pathogenic human CoVs, and that protection required IFN-γ and was depended on early induction of robust innate and virus-specific CD8+ T cells (123).

SARS-CoV-2 has shown replication, not only in human peripheral monocytes and macrophages, but also to directly infect T lymphocytes during primary infection through S protein-mediated membrane fusion, likely contributing to the severe lymphocytopenia that is a diagnostic indicator common in COVID-19 patients (51, 100, 124). SARS-CoV has also been shown to infect dendritic cells (DC), the central coordinators of the immune response, leading to impaired DC maturation and their high expression of the pro-apoptotic protein TRAIL (125). Instead of facilitating lymphocyte activation and expansion in numbers, this likely induces lymphocyte death and represents another mechanism of immune escape and intensification of the immunocompromised state of SARS-CoV patients (126). Similar mechanisms could contribute to lymphopenia and dysfunctional immune responses observed in severe COVID-19 patients. In the elderly, immune evasion by SARS-CoV-2 is probably made worse due to the reduced number and function of antigen presenting cells (APCs) (127). Multiple studies have been performed in mouse models describing the importance of type 1 CD4+ and CD8+ T cells in SARS-CoV (128, 129), with one study establishing that virus-specific memory CD8+ T cells provided substantial protection from lethal closely related SARS-CoV infection in a mouse model, emphasizing the importance of a cell-based type 1 immune response for survival of SARS infections (102). The majority of the many current vaccine strategies against SARS-CoV-2 rely on unadjuvanted or self-adjuvanted vaccines (e.g., RNA and DNA vaccines), or type 2 immune response promoting vaccines (e.g., alum adjuvanted, or unadjuvanted peptide or protein based vaccines) (113, 130, 131). Rather than promoting type 1 immunity, such approaches are likely to mostly lead to induction of type 2 responses which, as previously discussed, are unlikely to be effective against SARS-CoV-2 (100). Existing CoV antibodies have, in the case of host challenge with the same virus, enhanced viral load and disease severity in feline coronavirus or feline infectious peritonitis virus (FIPV) infections. This phenomenon is known as antibody-dependent enhancement (ADE) of viral infection (132, 133). In FIPV infection ADE can be induced by the presence of sub-neutralizing levels of anti-FIPV spike antibodies (134). Unlike in dengue virus infections, ADE in feline coronavirus infection is caused by re-infection with the identical serotype virus (124). It should be noted that mice, often used for preclinical safety evaluation of vaccines, lack FcγRIIa, the main FcγR on human cells linked to ADE induction (135, 136). Increasing viral entry into permissive cells and/or triggering excessive production of pro-inflammatory cytokines has made ADE a significant concern with several viruses, including the closely related SARS-CoV (137, 138). Concerns have also been
IL-6 is an indispensable cytokine that initiates innate immune responses. It has been utilized as emergency interventions in COVID-19 patients, with ARDS and hypotension, although so far with mixed results. Based on success in hematological and oncology settings, several IL-6 antagonists (tocilizumab, sarilumab as well as siltuximab) have been suggested significant harm in critical cases (147). Based on success in hematological and oncology settings, several IL-6 antagonists (tocilizumab, sarilumab as well as siltuximab) have been utilized as emergency interventions in COVID-19 patients with ARDS and hypotension, although so far with mixed results (148). IL-6 is an indispensable cytokine that initiates innate immune responses.

Cytokine Storm

Direct comparisons in the literature of clinical observations in COVID-19 patients with IL-6 induced “cytokine storm” or cytokine release syndrome (CRS) should be made with caution (25, 141, 142). For example, cytokine levels during hyperinflammation in COVID-19 are multiple orders of magnitude lower than has been observed during cancer treatments by adoptive cell transfer of autologous T cells modified with chimeric antigen receptors (CAR-T cell therapy), a classical example for CRS (143, 144). Although, CRS is normally treated with extensive use of steroids, the clinical evidence does not support corticosteroid treatment for COVID-19 induced lung injury and interfered with clearance (145). In SARS and MERS, corticosteroid use did not improve patient mortality and also resulted in delayed viral clearance (11). It should be noted that a recent preprint of a randomized-controlled trial observed that therapy with dexamethasone lead to a significant reduction of death in ventilated patients, as well as for patients on supplemental oxygen, while no benefit was shown in mild cases (146). A recent review of corticosteroid use in the management of COVID-19 revealed a mixed picture from five available studies. In four retrospective studies and one quasi-prospective study, three studies indicated a benefit, while the other two studies showed no benefit, and one sub-study even suggested significant harm in critical cases (147). Based on success in hematological and oncology settings, several IL-6 antagonists (tocilizumab, sarilumab as well as siltuximab) have been utilized as emergency interventions in COVID-19 patients with ARDS and hypotension, although so far with mixed results (148). IL-6 is an indispensable cytokine that initiates innate immune responses after pathogen invasion or tissue damage by stimulating acute phase reactions, immune responses, hematopoiesis, and activation of numerous internal organs to prepare for host defence (149). Therefore, IL-6 and other cytokines like tumor necrosis factor (TNF)-α are indispensable during functional activation of monocytes, macrophages and DCs before or early during COVID-19 disease, as they are in diseases caused by other respiratory viruses (150). However, in later disease stages increasing immune dysregulation and T cell apoptosis, macrophages and IL-6 may accelerate immune imbalance (151).

Preventing and treating coronavirus infections will likely need a multiphasic approach to prophylaxis and therapy, especially in vulnerable populations. It will be important to use the right tools at the right time to avoid unintended and potentially counterproductive consequences. The right set of immunomodulators would likely be able to prepare and boost innate immune defences to either ensure appropriate, effective responses to infection and/or guide the development of suitable, protective immunity in response to potentially suboptimal adjuvanted first generation vaccines. Antiviral treatments or combinations of them will be most useful during early infection, while a different set of immunomodulators may be needed in late stage and severe disease, where a dysregulated antiviral response can cause deadly collateral damage.

MICROBIAL “OLD FRIENDS” AND BCG

Some microbes have existed throughout human history, with evidence of their presence in hunter-gatherer societies, shaping the evolution of the human immune system (152). Some of these microbes, branded as “old friends” or “old infections,” are thought to be so intricately involved in this process that they are required for human immunity to develop and function properly (153, 154). Examples of such microbes are harmless mycobacteria that are present in the environment and used to be prevalent in water and food, where they were postulated to have a “training” impact on the human immune system (153). In addition, “paleolithic” strains of Mycobacterium tuberculosis (Mtb) that were less pathogenic than modern strains could have contributed to this process (152). Environmental Mycobacteria can provoke type 1 responses, as has been shown in mouse models and human cell-based in vitro studies for heat killed Mycobacterium bovis, NCTC13365 (IMM-101) and Mycobacterium vaccae, NCTC11659 (IMM-201) (155–158). This is also the case for the attenuated strain of Mycobacterium bovis, BCG (159). However, modern, urban societies are often missing frequent exposure to environmental bacteria such as M. obuense and M. vaccae – they literally have lost touch with their “old friends” and may need “new old friends,” to support type 1 immune responses.

Remarkably, several observational studies have recently proposed that countries with active BCG vaccination in place had fewer confirmed COVID-19 cases and related deaths (160–162). These observational studies should be appraised with caution, since there are many confounding factors in interpreting such correlative data in the context...
during the COVID-19 pandemic (163). There is no peer-reviewed data yet, or a clear scientific hypothesis about the proposed mechanism of action, to explain how decades later a single BCG vaccination could provide long lasting, heterologous protection against a viral disease. In contrast, there are evidence-based arguments, acutely relevant to the COVID-19 pandemic, regarding how BCG or type 1 immune inducing environmental Mycobacteria could provide protection against severe COVID-19 in the form of the trained immunity hypothesis.

**TRAINED IMMUNITY UTILITY FOR VACCINES**

Contact with specific microbial stimuli can induce long-lasting epigenetic changes in innate immune cells, which not only results in an enhanced response to a second challenge by the same microbe, but also to unrelated microbial insults (164). Referred to as “trained” immunity or innate immune memory, this process was originally shown for the BCG vaccine (165, 166). This concept may help explain previous observations that, after infection or vaccination, prototypical innate immune cells like monocytes, macrophages and NK cells undergo long-term changes in their functional programs, promoting host resistance against a wide spectrum of pathogens, including fungi, bacteria and viruses (167). Trained immunity is thought to be responsible for the observation in clinical studies that childhood vaccination with BCG correlates with protection against 30–50% of infections with any known pathogen, including viruses (168, 169). Additionally, a reduction in childhood mortality, unrelated to the prevention of tuberculosis (TB), has been observed (169). Similar positive effects have been shown for BCG vaccinations in adults, including improving responses to Influenza vaccination (170). A study in Guinea-Bissau showed that BCG reduced the incidence of respiratory syncytial virus infection (171). Importantly for the at-risk populations for severe COVID-19, it was shown that BCG had a similar protective effect on respiratory tract infections in older individuals in Indonesia (172). In addition, a clinical trial performed in older individuals in Japan established protection against pneumonia after pneumococcal, influenza and BCG vaccinations (173). Further confirmation of this effect has been demonstrated in a randomized controlled trial in which BCG vaccination protected against experimental infection of a yellow fever virus (174). In summary, BCG vaccination has been shown to protect against a range of viral infections (175). Related to this, when vaccination against smallpox was introduced around 200 years ago, positive side-effects such as protection against measles, scarlet fever and whooping cough, among others, were noticed (176).

Monocytes from healthy human volunteers were stimulated *ex vivo* with unrelated pathogens and displayed enhanced pro-inflammatory cytokine production of IL-1β, TNF and IL-6 after BCG vaccination (165). Experimental studies in mice have delineated that some of the mechanisms by which BCG induces these protective effects. For example, in mice, reduced viral titers of influenza A virus rely on macrophages (177). Subcutaneous administration in mice of muramyl dipeptide (MDP), part of the mycobacterial cell wall, protected against vaccinia virus and herpes simplex virus type 2 (HSV2) infections (178). Newborn mice could be protected with BCG from infection by HSV2 (179). More recently, other inducers of trained immunity have also been identified, including β-glucan, which has been shown to induce protective trained immunity in human monocytes and against Mtb infection in mice (180). The combination of these observations and others led to the proposal of the development of trained immunity-based vaccines (TIbV).

TIbVs aim to induce a pre-activated or “poised” activation state in innate immune cells. In this way they are, unlike conventional vaccines, theoretically able to stimulate much broader immune responses that are not focused on just one specific pathogen (181). This capacity of TIbVs to promote responses beyond their nominal antigens may be particularly useful when conventional vaccines are not available, or when multiple co-infections and/or recurrent infections arise in susceptible individuals at the same time, as is the case in the current pandemic COVID-19 health emergency. At least six different countries, including the Netherlands and Australia, have initiated clinical trials with the intent of investigating BCG vaccination as TIbV to protect HCW from symptomatic or serious COVID-19 infections (175, 182, 183).

In general, BCG is regarded a safe vaccine in young and healthy individuals. However, as is the case with any vaccines containing live attenuated organisms, there is a possibility of adverse events, such as disseminated BCG disease, in the elderly and immunocompromised. For this reason, in cancer patients, who represent a high-risk group for severe COVID-19 infection, BCG is contraindicated in several countries highly impacted by the pandemic, including the United States and Canada (184, 185). As a result, populations likely to benefit most from the potential of TIbVs and at the highest risk of a severe COVID-19 disease (e.g., cancer patients, frail elderly, or other people with impaired immune systems), cannot be included in BCG vaccination strategies. Despite the potential promise for mitigation of the COVID-19 pandemic, a major obstacle to its quick, rational deployment is the fact that the BCG vaccine comprises of a number of genetically distinct substrains (186). These have subsequently been shown to have different immunological properties, such as variable virulence and efficacy as a tuberculosis vaccine in mice (187). This substrain diversity may also help explain some inconsistencies following BCG use, such as variable Th1 or Th2 induction and side-effects (188). In clinical use, no evidence was found that vaccination efficacy against TB was associated with a specific BCG strain; however, a Th1 or Th2 bias was not investigated in that study (189). It has also been shown that the immune response can be directed from Th1 to mixed Th1/Th2, depending on the dose of BCG used (190). Bacille Calmette-Guérin is not routinely injected more than once, but an earlier study showed that, of six patients who were given a second inoculation of the BCG vaccine, three showed persistent cutaneous granulomas (191). A recent clinical study also observed evidence of a protective effect against persistent Mtb infection after BCG revaccination
Although repeat treatment with BCG has been used in the past on oncology as an adjuvant to boost cell-based cancer vaccines (193).

**Mycobacterium obuense (IMM-101)**

IMM-101 is a preparation of heat killed, whole cell, *M. obuense* National Collection of Type Cultures (NCTC) 13365, one of over 100 named species within the genus *Mycobacterium*, and an “old friend.” *M. obuense* is a rapidly dividing mycobacterium that normally grows as an environmental saprophyte (194). Since IMM-101 is a heat killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms (195). Moreover, one can speculate that IMM-101, by virtue of its potent type 1 inducing ability, will counter-regulate type 2 responses, helping to explain the encouraging clinical results to date in melanoma and pancreatic cancer (195, 196). An open label, Phase 2 study of IMM-101 in combination with checkpoint inhibitor therapy Nivolumab is currently underway in patients with advanced melanoma in the United Kingdom (197).

The total number of patients exposed to IMM-101 across clinical trials and compassionate programs without any unexpected adverse events has been over 345. The mode of action of IMM-101 is in the process of being elucidated, but it has been shown to be a multifaceted modulator of both innate and adaptive arms of the immune system (158). Experiments with mouse and human immune cells have shown that IMM-101 is very effective in inducing cytokine expression by innate immune cells, including M1 polarization and enhanced antigen presentation by DCs, leading to a typical type 1-biased immune response (Figures 1, 2) (198, 199). Systemic activation of, and IFN-γ production by, multiple immune cell types (158), including innate immune cells like NK cells, T cells expressing gamma/delta receptors (γδ-T cells) and natural killer T (NKT) cells (157, 200) (Figure 1), is based in part on the promotion and activation of CD4+ Th1, and CD8+ CTLs, with increased production of the cytokine IFN-γ in *in vitro* and *in vivo* (198–202). It is also possible that, in this setting, IMM-101 may act to train monocytes for enhanced M1 function (Figure 2). NK, γδ-T, NKT, Th1 cells, and CTLs, are well-known to play crucial roles in anti-viral and anti-tumor responses that can kill infected or tumor cells. This diverse mechanism of action of IMM-101, the safe promotion of a broad, systemic innate and adaptive type 1 immune response, may provide a rationale for considering its use against SARS-CoV-2.

Interestingly, BCG has been shown to promote activation of Vγ9Vδ2 T cells, the major subset of γδ T cell pool in human peripheral blood with a previously proposed protective role against SARS-CoV (see above) (203). Vδ2 T cells are exactly the cell-subtype that has been shown to also be activated by IMM-101 stimulation, in some experiments showing a stronger ability to do so than BCG (157). γδ T cells normally only represent a minor subset in peripheral blood, but can rapidly proliferate following infection with certain pathogens, expanding from 1% to over 50% of circulating T cells within a week (204, 205).
FIGURE 2 | BCG and environmental mycobacteria promote M1 macrophages and are likely to induce trained immunity. (A) Treatment with mycobacterial immunomodulators induce polarization of M1 macrophages along with “trained” inflammatory monocytes with enhanced M1 function, which can result in enhanced viral clearance (164–166, 199). (B) During innate immune training, innate cells undergo long-term cellular reprogramming. Unlike classical antigen-specific responses seen with adaptive immunity, this reprogramming results in increased capacity to respond to secondary challenges from a variety of pathogens and forms the basis of trained-immunity based vaccines (170–172, 181).

It is noteworthy that a large majority of Vδ2 T cells co-express Vγ9 in humans, and were shown to be important to overcome SARS-CoV infection (54, 206).

In addition to Th1 cells, CTLs and γδ T cells, NK and NKT cells also play key protective roles during viral infection (207, 208), and the potential importance of improving the NK...
cell and CTL response at the early stage of SARS-CoV-2 infection has already been highlighted (22). Under the umbrella of trained immunity, broad protection could be achieved by systemically increasing the non-specific effector response of innate immune cells (e.g., macrophages, NK, NKT, and γδ T cells) while also enhancing DC activation and ability to promote adaptive T cell (e.g., Th1 and CTL) and B cell responses to both specific and non-related (bystander) antigens, all of which have been shown for IMM-101 (Figure 1) (198, 199).

Several studies have shown that the effects of IMM-101 are in part mediated by TLR2/1, and to a lesser extent, TLR2/6 (198, 199). TLR2 has been shown to directly trigger Th1 effector functions in mice (209). Subsequently, it was shown that IMM-101 activates human Mincle reporter cell lines (158, 227). It is noteworthy that Mincle can suppress TLR 4 activation (211) and TLR4 has been proposed to have a central role in the initiation of damaging inflammatory responses during different acute viral infections (30). In contrast to BCG, IMM-101 does not activate TLR4 (198, 199, 212). In a similar manner, Mincle suppresses Th17 immune responses, which as well have been suggested in coronavirus immunopathology and vaccine-induced immune enhancement (213, 214). It was only recently discovered that activation of the Mincle receptor is a key activation pathway for Complete Freund’s Adjuvant (CFA), the “gold standard” adjuvant for eliciting cell-mediated immunity (CMI) in research models (215–217).

Effective and enhanced viral and tumor antigen cross-presentation requires TLR2 or TLR3 activation of human DCs (218). Mouse CD8α+ DCs express TLR7 and TLR9, in addition to the TLR2 family and TLR3, whereas the only relevant corresponding cross-presenting human CD141+ DCs in lymph nodes exclusively express the TLR2 family and TLR3 (218, 219). Importantly, analysis of the susceptibility of primary human DC subsets to viral infections has shown that

FIGURE 3 | BCG and “new old friends” have potential utility for prevention of severe COVID-19 in a number of ways. Bacille Calmette-Guérin (BCG) and other mycobacterial immunomodulators initiate robust type 1 immune responses and innate immune training, leading to tissue type 1 immune cell infiltration and elevated basal systemic type 1 inflammation (156–159, 164–166, 198–202). This allows for potential alteration of disease trajectory through prevention of viral establishment, enhanced viral killing or as a vaccine adjuvant to enhance immunity.
CD141+ DCs have an innate resistance to infection by a broad range of enveloped viruses, including HIV and influenza virus. In contrast, CD1c+ DCs are susceptible to infection, which enables viral antigen production, but impairs their immune function and survival. This has led to the conclusion that inclusion of TLR2 or TLR3 agonists would be the most direct mechanism to enable enhanced viral and tumor antigen cross-presentation, likely necessary for effective cancer immunotherapy (218) and viral clearance (220). Interestingly, previous work has suggested that vaccine-induced eosinophil immunopathology in the lungs after SARS-CoV infection could be avoided with the use of TLR3 agonists as adjuvants (221). However, use of TLR3 agonists may have to be viewed with caution in the context of COVID-19, based on observations of harmful contributions of TLR3 to influenza A virus-induced acute pneumonia in mice. In that scenario, TLR3-influenza A virus interaction critically contributed to the debilitating effects of a detrimental host inflammatory response (222). Further, it has been shown that TLR4 signaling induces TLR3 up-regulation in alveolar macrophages during ALI, and that TLR4 and TLR3 in macrophages are an important determinant in ALI (223), and that there is an association between respiratory syncytial virus TLR3-mediated immune responses and chronic obstructive pulmonary disease exacerbation frequency (224). TLR2 activation of macrophages leads to M1 polarization, and a shift from M2 into M1 macrophages (225). In addition, it has been shown that TLR2 activation of macrophages can impair activity of M2-like macrophages (226). IMM-101 activates TLR2 and not TLR4 and leads to M1 macrophage polarization (Figure 2) (198, 199). The combined characteristics of IMM-101 have led to the approval by Health Canada of a randomized, Phase 3 trial of immunization with IMM-101, versus observation, for the prevention of severe respiratory and COVID-19 related infections in cancer patients at increased risk of exposure (210).

DISCUSSION

In this review, we have presented an overview of current knowledge of the innate, adaptive and dysfunctional immune responses to SARS-CoV-2, in relation to other closely related coronaviruses. We have outlined the responses that may be required for successful vaccine development against COVID-19, while highlighting potential risks during this development, especially for the elderly. Early clinical data look promising, while highlighting potential risks during this development, required for successful vaccine development against COVID-coronaviruses. We have outlined the responses that may be needed to mitigate potential dangers of well-intended, but potentially flawed, vaccines that are being expedited to large parts of high-risk populations around the globe. In addition, the potential utility of “new old friends” as T1bVs like BCG or heat killed environmental bacteria such as IMM-101, that act as multigated, systemic immunomodulators of the innate and adaptive immune system have been described. Studies to show BCG’s and IMM-101’s potential utility for the prevention of severe COVID-19 are underway or planned, with the potential to change immune status and alter disease trajectory in multiple ways (Figure 3): (i) as prophylaxis, with enhanced innate memory and increased basal systemic type 1 immunity preventing viral establishment; (ii) as a treatment for patients in early stages of disease, with increased local and systemic type 1 inflammation enhancing killing of virally infected host cells; (iii) as an adjuvant for future COVID-19 vaccines. Thus, BCG and IMM-101 have the potential to be rapidly deployed to address the COVID-19 emergency and the challenge posed by the current lack of effective treatments and vaccines, leading to a high unmet medical need. With other routes of vaccine and therapy development likely to take many months or years to develop, or even reformulate, the help of “new old friends” such as BCG and IMM-101 may be precisely what we need in the current pandemic crisis.

AUTHOR CONTRIBUTIONS

T-OK and AD conceived the idea for the review and wrote the manuscript, with constructive input from AM and AG. AG prepared display items under the supervision of AM. All authors approved the final version of the manuscript.

FUNDING

T-OK receives a salary from Immodulon Therapeutics Ltd. AG is a recipient of an MRC (UK) NPIF Ph.D. studentship, which is part funded by Immodulon Therapeutics Ltd. AM receives laboratory support by grants or studentships from the MRC, the BBiSRC, the EPSRC, Immodulon Therapeutics Ltd., and MCCIR core. AD received grant support from the ICVI program grant 2017-2022 and LDNPharma project grant 2017-2021.

ACKNOWLEDGMENTS

The authors thank B. Trease, Mediscribe Consulting Ltd., for technical editing.

REFERENCES

1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. (2020) 26:450–2. doi: 10.1038/s41591-020-0820-9
2. Zhan M, Qin Y, Xue X, Zhu S. Death from Covid-19 of 23 health care workers in China. N Engl J Med. (2020) 382:2267–8. doi: 10.1056/nejmc2005696
3. Baylis D, Bartlett DB, Patel HP, Roberts HC. Understanding how we age: insights into inflammmaging. Longev Healthspan. (2013) 2:8.
4. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. (2020) 10:783–91.
5. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Global Health. (2020) 8:e1003–17.
6. Doyle JD, Beacham L, Martin ET, Talbot HK, Monto A, Gaglani M, et al. Relative and absolute effectiveness of high-dose and standard-dose
Frontiers in Immunology | www.frontiersin.org 13 September 2020 | Volume 11 | Article 2059

Enhancing Innate Immunity Against COVID-19

influenza vaccine against influenza-related hospitalization among older adults–United States, 2015–2017. Clin Infect Dis. (2020)ciaa1160. doi: 10.1093/cid/ciaa1160 [Epub ahead of print].

7. Angka L, Markert M, Ardlonino M, Auer RC. Is innate immunity our best weapon for flattening the curve? J Clin Investig. (2020) 130:3954–6.

8. Le Thanh T, Aubert K, Kumar A, Gomez Roman R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. (2020) 19:305–6. doi: 10.1038/s41573-020-00073-5

9. De Groot AS. Is innate immunity our best weapon for flattening the curve? Adv Virus Res Clin Microbiol. (2020) 579:270–3. doi: 10.1016/s0028-1–0140.0035421.

10. Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonry immunopathology on challenge with the SARS virus. PloS One (2012) 7:e35421. doi: 10.1371/journal.pone.0035421.

11. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. (2017) 39:529–39. doi: 10.1007/s00281-017-0629-x

12. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. (2020) 5:536–44. doi: 10.1038/s41564-020-0695-z

13. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia OUTBREAK in Wuhan of unknown cause. N. Engl. J Med. (2020) 382:797–806. doi: 10.1056/nejmoa2001191

14. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia OUTBREAK in Wuhan of unknown cause. N. Engl. J Med. (2020) 382:797–806. doi: 10.1056/nejmoa2001191

15. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Immun Ageing. (2020) 17:533–5. doi: 10.1038/s41423-020-00413-0

16. Teuwen L-A, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. (2020) 20:389–91. doi: 10.1038/s41577-020-0343-0

17. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben CJ, et al. Platelet gene expression and function in COVID-19 patients. Blood. (2020) 135:2228–33. doi: 10.1182/blood.2020007214 [preprint].

18. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. (2020) 191:145–7. doi: 10.1016/j.thromres.2020.08.013

19. Minton K. DAMP-driven metabolic adaptation. Nat Rev Metab. (2020) 20:1. doi: 10.1038/s41579-019-0258-9

20. Teuwen L-A, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. (2020) 20:389–91. doi: 10.1038/s41577-020-0343-0

21. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben CJ, et al. Platelet gene expression and function in COVID-19 patients. Blood. (2020) 135:2228–33. doi: 10.1182/blood.2020007214 [preprint].

22. Lam VC, Linder LL. NK cells in host responses to viral infections. Immun Ageing. (2020) 17:8. doi: 10.1182/blood.2020007214 [preprint].

23. Yang P, Chen X, Wang J, Hu Z, Huang R, et al. The conserved coronavirus macrodomain promotes virulence and suppresses pathogenesis. Cell Microbiol. (2018) 20:389–91. doi: 10.1111/1365-3157.12826.
by CD4+ Th1 cells. *J Immunol.* (2011) 187:1157–65. doi: 10.4049/jimmunol.1100889

51. Villa M, Harcourt BH, Hickman CJ, McGrew M, Tamin A, Goldsmith CS, et al. SARS-coronavirus replication in human peripheral mononuclear/macrophages. *Virus Res.* (2005) 107:93–101. doi: 10.1016/j.virusres.2004.09.004

52. Santi S, Jenkins MR, Dash P, Watson KA, Wang Z, Pizzolla A, et al. Human γδ T-cell receptor repertoire is shaped by influenza viruses, age and tissue compartmentalisation. *Clin Transl Immunol.* (2019) 8:e1079.

53. Davey MS, Willcox CR, Hunter S, Kasatskaya SA, Remmerswaal EBM, Salim M, et al. The human Vγ2+ T-cell compartment comprises distinct innate-like Vγ9+ and adaptive Vγ9- subsets. *Nat Commun.* (2018) 9:1760.

54. Poccia F, Agrati C, Castilletti C, Bordi L, Gioia C, Horejsh D, et al. Anti-SARS-CoV-2 infection: involvement of γδ T cells. *Cell Mol Immunol.* (2020) 17:771–2. doi: 10.1038/s41424-020-0473-0

55. Rijkers G, Vervenne T, van der Pol P. More bricks in the wall against SARS-CoV-2. *Arch Virol.* [Preprint]. (2020):doi: 10.1007/s00705-020-04198-9

56. Shi Y, Tan M, Chen X, Liu Y, Huang J, Ou J, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. *Clin Transl Immunol.* (2020) 9:1760.

57. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in recovered patients from India. *Lancet Respir Med.* (2020) 8:420–9. doi: 10.1016/s2213-2600(20)30076-x

58. Wang Z, Zhu L, Nguyen THO, Wan Y, Sant S, Quinones-Parrama SM, et al. Clonally diverse CD38+(HLA-DR+)+(CD57+) T cells persist during fatal H7N9 disease. *Nat Commun.* (2018) 9:824.

59. Chen X, Ling J, Mo P, Zhang Y, Jia J, Mo Z, et al. Restoration of lymphocyte and lymphocyte subsets in patients with severe acute respiratory syndrome. *J Infect Dis.* (2003) 187:1157–65. doi: 10.1086/381535

60. Peng H, Yang LT, Li J, Lu ZQ, Wang LY, Koup RA, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. *Arch Virol.* (2009) 154:1093–9. doi: 10.1007/s00705-009-0409-4

61. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. The emerging SARS-CoV2 epidemic in Toronto, Canada, November 2002 to March 2003. *J Infect Dis.* (2003) 188:1909–17. doi: 10.1086/378587

62. Grifoni A, Weiskopf D, Ramirez SL, Mateus J, Dan JM, Morebacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell.* (2020) 181:1489–501 e15.

63. Qin C, Zhou L, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. *Syndr Hum Retrovirol* [Preprint]. (2020):doi: 10.1007/s00705-020-04198-9

64. Pocchiari M, Rassi A, Cianciulli P, Alberti S, Allemanni C, Amoroso E, et al. Differences in T cell reactivity between asymptomatic and symptomatic SARS-CoV-2 infected patients from Italy. *J Virol.* (2020) 94:0409-6.

65. Xia Y, Li Y, Zhang S, He Q, Sun H, Wang T, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. *Virology.* (2006) 351:466–75. doi: 10.1016/j.virol.2006.03.036

66. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia in patients with COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med.* (2020) 8:420–9. doi: 10.1016/s2213-2600(20)30076-x

67. Xie Y, Wu W, Zhang F, Wang JY, Ni AP. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. *Clin Infect Dis.* (2003) 37:857–9. doi: 10.1086/378587

68. Li L, Wo J, Shao J, Zhu H, Wu N, Li M, et al. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. *J Clin Virol.* (2003) 28:239–44. doi: 10.1016/s1386-6532(03)00195-1

69. Li L, Shao J, Zhu H, Wu N, Li M, et al. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. *J Clin Virol.* (2003) 28:239–44. doi: 10.1016/s1386-6532(03)00195-1

70. Boyer JL, Boyer JD, Bocchini JA, Drouilhet R, Drolet RM, et al. Identification of severe acute respiratory syndrome in Canada. *N Engl J Med.* (2003) 348:1995–2000.

71. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong, *N Engl J Med.* (2003) 348:1977–85.

72. Guo B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). *Front Immunol.* (2020) 11:287. doi: 10.3389/fimmu.2020.00827

73. Qin B, Zhu Y, Yang X, Wang C, Liu Y, et al. Respiratory virus infections in severe acute respiratory syndrome patients. *Arch Virol.* (2005) 150:1453–62. doi: 10.1007/s00705-005-1158-2

74. Peng H, Yang LT, Li J, Lu ZQ, Wang LY, Zuo ZX, et al. Long-lived effector/central T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV-2) S antigen in recovered SARS patients. *Clin Immunol.* (2006) 122:171–8. doi: 10.1016/j.clim.2006.05.002

75. Li L, Jia J, Yuan H, Cao X, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. *Vaccine.* (2016) 34:2008–14. doi: 10.1016/j.vaccine.2016.02.063

76. Fan YY, Huang ZT, Li L, Wu MH, Yu T, Koup RA, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. *Arch Virol.* (2009) 154:1093–9. doi: 10.1007/s00705-009-0409-4

77. Chen H, Hou J, Jiang X, Ma S, Meng M, Wang B, et al. Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. *J Immunol.* (2005) 175:591–8. doi: 10.4049/jimmunol.175.1.591

78. Janice Oh HL, Ken-En Gan S, Bertoletti A, Tan YJ. Understanding the T cell immune response in SARS coronavirus infection. *Emerg Microbes Infect.* (2012) 1:e23.
HIV infection impact viral set point. *Immunity*. (2015) 45:591–604. doi: 10.1016/j.immuni.2015.08.012

98. Drosten C, Meyer B, Muller MA, Corman VM, Al-Masri M, Hossain R, et al. *Severe acute respiratory syndrome coronavirus infection*. *J Virol* (2013) 87:2449–66. doi: 10.1128/jvi.01505-14

99. Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. *Immunity in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD1 resistance*. *Nat Immunol*. (2019) 20:1231–43. doi: 10.1038/s41590-019-0441-y

100. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. *SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor*. *Cell*. (2020) 180:271–80.e8.

101. Lu F, Li W, Farzan M, Harrison SC. *Structure of SARS coronavirus spike receptor-binding domain complexed with receptor*. *Science*. (2005) 310:1084–8. doi: 10.1126/science.1116480

102. Earnest JT, Hantak MP, Li K, McCray PB Jr, Perlman S, Gallagher T. *The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases*. *PLoS Pathog.* (2017) 13:e1006546. doi: 10.1371/journal.ppat.1006546

103. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. *Neutralizing antibody mechanisms of coronavirus cross-species transmission*. *J Virol* (2015) 90:975–85. doi: 10.1128/jvi.02980-14

104. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, et al. *Intrafamilial exposure to SARS-CoV-2 induces cellular immune response mechanisms of coronavirus cross-species transmission*. *J Virol* (2020) 94:e00670-20. doi: 10.1128/jvi.00670-20

105. Anft M, Panisikati K, Blazquez-Navarro A, Doevelaar AAN, Siebert F, Hoelzer D, et al. *Possible role of immunopathogenesis in COVID-19 progression*. *medRxiv* [Preprint]. (2020). doi: 10.1101/2020.04.28.20030809

106. Verma V, Shiramaki RK, Ahmad S, Dai W, Wang H, Lu S, et al. *PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)/CD38(hi) cells and anti-PD-1 resistance*. *Nat Immunol*. (2019) 20:1231–43. doi: 10.1038/s41590-019-0441-y

107. Graham RL, Baric RS. *Recombination, reservoirs, and the modular spike: implications of emerging respiratory coronaviruses*. *Nat Rev Microbiol*. (2020) 18:477–83. doi: 10.1038/s41579-020-0365-4

108. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. *The spike protein of SARS-CoV—a target for vaccine and therapeutic development*. *Nat Rev Microbiol*. (2009) 7:226–36. doi: 10.1038/nrmicro2090

109. Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, et al. *PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)/CD38(hi) cells and anti-PD-1 resistance*. *Nat Immunol*. (2019) 20:1231–43. doi: 10.1038/s41590-019-0441-y

110. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. *SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor*. *Cell*. (2020) 180:271–80.e8.

111. Li F, Li W, Farzan M, Harrison SC. *Structure of SARS coronavirus spike receptor-binding domain complexed with receptor*. *Science*. (2005) 310:1084–8. doi: 10.1126/science.1116480

112. Earnest JT, Hantak MP, Li K, McCray PB Jr, Perlman S, Gallagher T. *The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases*. *PLoS Pathog.* (2017) 13:e1006546. doi: 10.1371/journal.ppat.1006546

113. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, et al. *Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC*. *Nature*. (2013) 495:251–4. doi: 10.1038/nature12005

114. Callaway E. *The race for coronavirus vaccines: a graphical guide*. *Nature*. (2020) 580:576–7. doi: 10.1038/d41586-020-01221-y

115. Deming D, Sheehan T, Heise M, Yount B, Davis N, Sims A, et al. *Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants*. *PLoS Med*. (2006) 3:e525. doi: 10.1371/journal.pmed.0030525

116. Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, et al. *T cell responses to whole SARS coronavirus in humans*. *J Immunol*. (2008) 181:5490–500.

117. van Doremalen N, Haddock E, Feldmann F, Meade-White K, Bushmaker T, Fischer RJ, et al. *A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques*. *Sci Adv*. (2020) 6:eaba8399. doi: 10.1126/sciadv.aba8399

118. Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, et al. *Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial*. *Lancet Infect Dis*. (2020) 20:816–26. doi: 10.1016/s1473-3099(20)30160-2

119. Mulligan MJ, Lyke KE, Kitchin N, Abelson J, Gurtman A, Lockhart SP, et al. *Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report*. *medRxiv* [Preprint]. (2020). doi: 10.1126/sciadv.aba8399

120. Low JS, Farsakoglu Y, Amezcuca Vesely MC, Sekif E, Kelly JB, Harman CCD, et al. *Tissue-resident memory T cell reactivation by diverse antigen-presenting cells imparts distinct functional responses*. *J Exp Med*. (2020) 217:e20192291.

121. van Doremalen N, Lambre T, Spencer A, Belij-Rammerstorfer S, Gillespie RA, et al. *SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness*. *bioRxiv* [Preprint]. (2020). doi: 10.1101/2020.06.11.20200160

122. Mulligan MJ, Lyke KE, Kitchin N, Abelson J, Gurtman A, Lockhart SP, et al. *Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report*. *medRxiv* [Preprint]. (2020). doi: 10.1126/sciadv.aba8399

123. Vasu J, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, et al. *PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance*. *Nat Immunol*. (2019) 20:1231–43. doi: 10.1038/s41590-019-0441-y

124. Takano T, Kawakami C, Yamada S, Sato T, Hohdatsu T. *Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection*. *J Vet Med Sci*. (2008) 70:1315–21. doi: 10.1292/jvms.70.1315

125. Law HK, Cheung CY, Sia SF, Chan YO, Peiris JS, Lau YL. *Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells*. *BMC Immunol*. (2009) 10:35. doi: 10.1186/1471-2472-10-35
126. Lau YL, Peiris JS, Law HK. Role of dendritic cells in SARS coronavirus infection. *Hong Kong Med J*. (2012) 18(Suppl. 3):28–30.

127. Zhao J, Zhao J, Legge K, Perlman S. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished Th2 cell responses upon viral infection in mice. *J Clin Invest*. (2011) 121:4921–30. doi: 10.1172/jci59777

128. Roberts A, Deming D, Paddock CD, Cheng A, Youn B, Vogel L, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. *PLoS Pathog*. (2007) 3:e5. doi: 10.1371/journal.ppat.0030005

129. Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. *J Virol*. (2010) 84:9318–25. doi: 10.1128/jvi.01049-10

130. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. *J Immunol*. (1999) 163:6448–54.

131. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. *J Immunol*. (1999) 163:6448–54.

132. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in SARS coronavirus-infected mice. *J Virol*. (2010) 84:9318–25. doi: 10.1128/jvi.01049-10

133. Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. *J Virol*. (2010) 84:9318–25. doi: 10.1128/jvi.01049-10

134. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. *Curr Opin Immunol*. (2002) 14:798–802. doi: 10.1016/s0140-6736(20)30317-2

135. Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J, et al. Neutralizing antibody response and SARS severity. *J Immunol*. (2001) 167:1753–62. doi: 10.4049/jimmunol.167.3.1753

136. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. *Curr Opin Immunol*. (2002) 14:798–802. doi: 10.1016/s0140-6736(20)30317-2

137. Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J, et al. Neutralizing antibody response and SARS severity. *J Immunol*. (2001) 167:1753–62. doi: 10.4049/jimmunol.167.3.1753

138. Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z, et al. RETRACTED ARTICLE: Mycobacterium bovis BCG Vaccination may be Protective Against Covid-19 Protective Against Covid-19. *Int J Mycobacteriol*. (2020) 9:475–81. doi: 10.1016/j.ijmyco.2020.02.006

139. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

140. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

141. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

142. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

143. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

144. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

145. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

146. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

147. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: a systemic review and a Clinician’s perspective. *Diabetes Metab Syndr*. (2020) 14:971–8. doi: 10.1016/j.dsx.2020.06.054

148. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

149. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

150. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

151. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

152. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2

153. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. (2020) 395:473–5. doi: 10.1016/s0140-6736(20)30317-2
beneficial nonspecific effects in the neonatal period? J Infect Dis. (2011) 204:245–52. doi: 10.1093/infdis/jir240

169. Higgins JP, Soares-Weiser K, Lopez-Lozano A, Haddow JG, Mathews F, et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccine in healthy volunteers: a randomized, placebo-controlled pilot study. J Infect Dis. (2015) 212:1930–8. doi: 10.1093/infdis/jiv332

170. Leentjens J, Kox M, Stokman R, Gerretsen J, van Crevel R, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine. (2005) 23:1225–7. doi: 10.1016/j.vaccine.2004.09.006

171. O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. (2020) 20:335–7. doi: 10.1038/s41577-020-0337-y

172. O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. (2020) 20:335–7. doi: 10.1038/s41577-020-0337-y

173. Mayr A. Taking advantage of the positive side-effects of smallpox vaccination. N Engl J Med. (2018) 379:138–49. doi: 10.1056/ n eng j med.1714021

174. Roseland: Organon Teknika Corporation. (2009). p. 62–6.

175. Bazzi S, Modjtahedi H, Mudan S, Achkar M, Akle C, Bahar GM. Immunomodulatory effects of heat-killed Mycobacterium bovis uboense on dendritic cells. Innate Immun. (2017) 23:592–605. doi: 10.1177/1703814916669408

176. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. (2014) 58:470–80. doi: 10.1093/ c di/cid790

177. Crooks J, Brown S, Brunet L, MacDonald A. The impact of combination treatment of IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense with other vaccines on immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun. (1996) 66:5743–50. doi: 10.1128/iai.66.12.5743-5750.1998

178. Mangtani P, Abubakar I, Beynon R, Pimpin L, Fine PE, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. (2018) 379:138–49. doi: 10.1056/ nejmoa1714021

179. Crooks J, Brown S, Gauthier A. The impact of IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense and calmette-guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. (2011) 43:185–90.

180. Crooks J, Brown S, Gauthier A. The effect of combination treatment of IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense with other vaccines on immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun. (1996) 66:5743–50. doi: 10.1128/iai.66.12.5743-5750.1998

181. Martino A, Sacchi A, Sanarico N, Spadaro F, Ramoni C, Carabella A, et al. dendritic cells derived from BCG-infected precursors induce Th2-like immune response. J Leukoc Biol. (2004) 76:827–34. doi: 10.1189/jlb.0703153

182. Kahlid S, Zaat S, Mekalanos JG. Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs. Innate Immun. (1985) 2:86–92. doi: 10.1080/14733099200182-2

183. Bazzi S, Modjtahedi H, Mudan S, Akle C, Bahr GM. Analysis of immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model. Immunobiology. (2015) 220:1293–304. doi: 10.1007/j.imb.2015.07.015

184. Crooks J, Brown S, Gauthier A. The effects of combination treatment of IMM-101, a heat-killed whole cell preparation of Mycobacterium bovis uboense on human blood dendritic cells. Innate Immun. (2017) 23:592–605. doi: 10.1177/ 1753425917727838

185. Martino A, Casetti R, Sacchi A, Poccia F. Central memory Vγ9Vδ2 T lymphocytes primed and expanded by bacillus Calmette-Guerin-infected dendritic cells kill mycobacterial-infected monocytes. J Immunol. (2007) 179:3057–64. doi: 10.4049/jimmunol.179.5.3057

186. Kahlid S, Zaat S, Mekalanos JG. Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs. Innate Immun. (1985) 2:86–92. doi: 10.1080/14733099200182-2

187. Zhang L, Hu HW, Chen FZ, Jin CY, Sun RF, Fan XY, et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol Ther. (2016) 24:398–405. doi: 10.1038/mt.2015.216

188. Martino A, Sacchi A, Sanarico N, Spadaro F, Ramoni C, Carabella A, et al. dendritic cells derived from BCG-infected precursors induce Th2-like immune response. J Leukoc Biol. (2004) 76:827–34. doi: 10.1189/jlb.0703153

189. Mangtani P, Abubakar I, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. (2014) 58:470–80. doi: 10.1093/cid/cid790

190. Power CA, Wei G, Brescher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun. (1996) 66:5743–50. doi: 10.1128/iai.66.12.5743-5750.1998

191. Douglas JM, Vontver LA, Stamm WE, Reeves WC, Remington JS, et al. Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes. Antimicrob Agents Chemother. (1985) 27:203–6. doi: 10.1128/iai.27.2.203

192. Crooks J, Brown S, Gauthier A. The effect of combination treatment of IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense with other vaccines on immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun. (1996) 66:5743–50. doi: 10.1128/iai.66.12.5743-5750.1998

193. Morton DL, Eliber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, et al. BCG, interleukin-12, and IFN-γ enhance the immunogenicity of subsequent influenza vaccine in healthy children. Vaccine. (2007) 25:2317–21. doi: 10.1016/j.vaccine.2006.11.038

194. Martino A, Sacchi A, Poccia F, Capioglio A, Grange T, Wallace M, Malkovsky M. Antiviral reactivities of gammahelix T cells. Microbes Infect. (2005) 7:518–28. doi: 10.1016/j.microinf.2004.12.009
205. Wang L, Kamath A, Das H, Li L, Bukowski JF. Antibacterial effect of human V gamma 2 delta 2 T cells in vivo. J Clin Invest. (2001) 108:1349–57.
206. Casorati G, De Libero G, Lanzavecchia A, Migone N. Molecular analysis of human gamma/delta cells from thymus and peripheral blood. J Exp Med. (1989) 170:1521–35. doi: 10.1084/jem.170.5.1521
207. Fehervari Z. Macrophages: damage control. Nat Immunol. (2018) 19:99. doi: 10.1038/s41590-017-0040-8
208. Vermeulen BL, Devriendt B, Olyslaegers DA, Dedeurwaerder A, Desmarets LM, Favoreel HW, et al. Suppression of NK cells and regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus. Vet Microbiol. (2013) 164:46–59. doi: 10.1016/j.vetmic.2013.01.042
209. Imanishi T, Hara H, Suzuki S, Suzuki N, Akira S, Saito T. Cutting edge: TLR2 directly triggers Th1 effector functions. J Immunol. (2007) 178:6715–9. doi: 10.4049/jimmunol.178.11.6715
210. ClinicalTrials.gov. Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO): ClinicalTrials.gov Identifier: NCT04442048. (2020). Available online at: http://clinicaltrials.gov/ct2/show/NCT04442048 (accessed June 22, 2020).
211. Greco SH, Mahmood SK, Vahle AK, Ochi A, Batel J, Deutsch M, et al. Mincle suppresses Toll-like receptor 4 activation. J Leukoc Biol. (2016) 100:185–94. doi: 10.1189/jlb.3a0515-18sr
212. Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol. (2003) 74:277–86. doi: 10.1189/jlb.0103026
213. Hotez PJ, Bottazzi ME, Corry DB. The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes Infect. (2020) 22:165–7. doi: 10.1016/j.micinf.2020.04.005
214. Wuthrich M, Wang H, Li M, Lerkautharat T, Hardison SE, Brown GD, et al. Fosinopril pedrosi-induced Th17-cell differentiation in mice is fostered by Dectin-2 and suppressed by Mincle recognition. Eur J Immunol. (2015) 45:2542–52. doi: 10.1002/eji.201545591
215. Chase MW. The cellular transfer of cutaneous hypersensitivity to tuberculin. Exp Biol Med. (1945) 59:134–5. doi: 10.3181/00379727-59-15006p
216. Landsteiner K, Chase MW. Experiments on transfer of cutaneous hypersensitivity to tuberculin. J Exp Med. (1942) 88:8597–614. doi: 10.1189/jvi.1942.88.1.8597
217. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, et al. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. (2014) 88:5977–614. doi: 10.1128/jvi.00983-14
218. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. (2006) 2:e53. doi: 10.1371/journal.ppat.0020053
219. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents nectritic cell antigens. J Exp Med. (2010) 207:1247–60. doi: 10.1084/jem.20092140
220. Shen KY, Song YC, Chen HH, Leng CH, Chen HW, Li HJ, et al. Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells. J Immunol. (2014) 192:4233–41. doi: 10.4049/jimmunol.1302850
221. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, et al. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. (2014) 88:5977–614. doi: 10.1128/jvi.00983-14
222. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. (2006) 2:e53. doi: 10.1371/journal.ppat.0020053
223. Ding X, Jin S, Tong Y, Jiang X, Chen Z, Mei S, et al. TLR4 signaling induces TLR3 up-regulation in alveolar macrophages during acute lung injury. Sci Rep. (2017) 7:34278.
224. Liu D, Chen Q, Zhu H, Gong L, Huang Y, Li S, et al. Association of respiratory syncytial virus Toll-like receptor 3-mediated immune response with COPD exacerbation frequency. Inflammation. (2018) 41:654–66. doi: 10.1007/s10753-017-0720-4
225. Deng Y, Yang J, Qian J, Liu R, Huang E, Wang Y, et al. TLR1/TLR2 signaling blocks the suppression of monocytic myeloid-derived suppressor cell by promoting its differentiation into M1-type macrophage. Mol Immunol. (2019) 112:266–73. doi: 10.1016/j.molimm.2019.06.006
226. Quero L, Hansen E, Manigold T, Tiaden AN, Kyburz D. TLR2 stimulation impairs anti-inflammatory activity of M2-like macrophages, generating a chimeric M1/M2 phenotype. Arthritis Res Ther. (2017) 19:245.
227. Kleen T-O. Novel immunomodulators and their combinations require a broad, adaptive clinical biomarker strategy. In Proceedings of the CYTO Virtual 2020 Conference, 4-5 August 2020, Philadelphia, PA. (2020).

Conflict of Interest: T-OK is an employee of Immodulon Therapeutics Ltd. AM is a member of the Scientific Advisory Board for Immodulon Therapeutics Ltd. AD is a recipient of an MRC (UK) NPIF PhD studentship, which is part funded by Immodulon Therapeutics Ltd. AG is a member of the Scientific Advisory Board for Immodulon Therapeutics Ltd. AM is

Copyright © 2020 Kleen, Galdon, MacDonald and Dalgleish. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.